Editor-in-ChiefMichael Stowasser, Brisbane, Australia   Michael is currently Director of the Hypertension Units and Co-Director of the Endocrine Hypertension Research Centre within the University of Queensland School of Medicine at Greenslopes and Princess Alexandra Hospitals in Brisbane. He has over 25 years clinical research experience in pathogenesis and management of hypertension and especially of endocrine varieties including primary aldosteronism, renovascular hypertension, pheochromocytoma and familial hyperkalemic hypertension. Working with mentor Richard Gordon, he helped to demonstrate that primary aldosteronism is at least 10 times more common than previously thought, and is the commonest specifically treatable and potentially curable form of hypertension. Ongoing studies are aimed at determining genetic bases for primary aldosteronism, examining non-blood pressure dependent effects of aldosterone excess, improving methods of detection, diagnostic workup and management of primary aldosteronism and exploring the pathogenesis and genetics of other salt sensitive forms of hypertension, including familial hyperkalemic hypertension.
EditorsSunil Nadar, Muscat, Oman  Dr Sunil Nadar is a senior consultant cardiologist at the Sultan Qaboos University Hospital, Muscat, Oman. He is listed on google scholar as one of the top ten researchers in Oman in 2016. He was previously a consultant cardiologist with the Heart of England NHS trust and an honorary senior lecturer with the University of Birmingham UK.
He had completed his postgraduate research with Professor Gregory Lip and Professor Gareth Beevers at the University of Birmingham UK, on hypertension and platelet function and has co-edited a book on Hypertension with Prof Lip.
His main research interests are platelet activation, hypertension, coronary artery disease, and coronary intervention. He is a fellow of the Royal college of physicians London and a Fellow of the European Society of cardiology.
J. Brian Byrd, Michigan, US
 Dr. J. Brian Byrd investigates human hypertension using laboratory investigation of novel biomarkers, clinical trials, and epidemiology. While training in Nancy J. Brown’s laboratory, he worked on the mechanism of ACE inhibitor-associated angioedema in a rodent model, a case-control study, a GWAS, and a randomized clinical trial of a new drug. He later served as an investigator for the SYMPLICITY HTN-3 pivotal clinical trial of renal artery denervation. His current interest is resistant hypertension, especially endocrine forms of hypertension. Recently, his laboratory has pioneered sensitive and specific assays to detect mineralocorticoid receptor-regulated gene expression in the supernatant of human urine. In addition, Dr. Byrd worked together with a group dedicated to improving the quality of studies involving exosomes, nanoscale vesicles secreted into biofluids that provide a novel source of physiologically relevant biomarkers, the work having now been published in Nature Methods. Beyond these and other research contributions, in 2017 Dr. Byrd and Casey Greene created the Research Symbiont Awards, which recognize excellence in data sharing. He is a principal investigator at the University of Michigan School of Medicine, where he is Assistant Professor in the Department of Internal Medicine’s Division of Cardiovascular Medicine. He is funded by several organizations, including the National Institutes of Health.
Social Media EditorCarlos Valencia-Hernández, UK
|
京公网安备 11010802027423号